

In the Claims

1-64. (Canceled)

65. (Previously Presented) A method of inhibiting leukocyte recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14), wherein the dosage form is linked to a site targeting moiety.

66-68. (Canceled)

69. (Previously Presented) A method of inhibiting leukocyte recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:27, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, or reverse D Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

70-72. (Canceled)

73. (Previously Presented) A method of inhibiting leukocyte recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

74-79. (Canceled)

80. (Previously Presented) A method of inhibiting leukocyte recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74, wherein the dosage form is linked to a site targeting moiety.

81-82. (Canceled)

83. (Previously Presented) A method of inhibiting leukocyte recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

84. (Previously Presented) A method of inhibiting leukocyte migration or recruitment comprising: administering to a mammal an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14) or CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

85. (Previously Presented) The method of claim 84 wherein Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14) or CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys is in a dosage form which linked to a site targeting moiety.

86. (Previously Presented) A method of inhibiting leukocyte migration or recruitment, comprising: administering to a mammal an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ

ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

87. (Previously Presented) The method of claim 86 wherein the peptide is in a dosage form which is linked to a site targeting moiety.

88. (Previously Presented) A method of inhibiting leukocyte migration or recruitment comprising: administering to a mammal an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14) or CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

89. (Previously Presented) The method of claim 88 wherein Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14) or CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys is in a dosage form which linked to a site targeting moiety.

90. (Canceled)

91. (Previously Presented) The method of claim 90 wherein the peptide is in a dosage form which is linked to a site targeting moiety.

92. (Canceled)

93. (Previously Presented) The method of claim 65, 69, 73, or 88 or 90 wherein the mammal is at risk of leukocyte migration or recruitment.